Do the combined blood pressure effects of exercise and antihypertensive medications add up to the sum of their parts? A systematic meta-review

Linda S Pescatello, Yin Wu, Simiao Gao, Jill Livingston, Bonny Bloodgood Sheppard, Ming-Hui Chen

ABSTRACT

Objective To compare the blood pressure (BP) effects of exercise alone (EXalone), medication alone (MEDSalone) and combined (EX+MEDScombined) among adults with hypertension.

Data sources PubMed, Scopus, Cumulative Index to Nursing and Allied Health Literature, SPORTDiscus and the Cochrane Library.

Eligibility criteria Randomised controlled trials (RCTs) or meta-analyses (MAs) of controlled trials that: (1) involved healthy adults ≥18 years with hypertension; (2) investigated exercise and BP; (3) reported preintervention and postintervention BP and (4) were published in English. RCTs had an EX+MEDScombined arm; and an EXalone arm and/or an MEDSalone arm; and MAs performed moderator analyses.

Design A systematic network MA and meta-review with the evidence graded using the Physical Activity Guidelines for Americans Advisory Committee system.

Outcome The BP response for EXalone, MEDSalone and EX+MEDScombined and compared with each other.

Results Twelve RCTs qualified with 342 subjects (60% women) who were mostly physically inactive, middle-aged to older adults. There were 13 qualifying MAs with 28,468 participants (~50% women) who were mostly Caucasian or Asian. Most RCTs were aerobic (83.3%), while the MAs involved traditional (46%) and alternative (54%) exercise types. Strong evidence demonstrates EXalone, MEDSalone and EX+MEDScombined reduce BP and EX+MEDScombined elicit BP reductions less than the sum of their parts. Strong evidence indicates EX+MEDScombined potentiate the BP effects of MEDSalone. Although the evidence is stronger for alternative than traditional types of exercise, EXalones elicits greater BP reductions than MEDSalone.

Conclusions The combined BP effects of exercise and medications are not additive or synergistic, but when combined they bolster the antihypertensive effects of MEDSalone.

PROSPERO registration number The protocol is registered at PROSPERO CRD42020181754.

INTRODUCTION

Hypertension is the most predominant risk factor for cardiovascular disease (CVD) affecting nearly one in two adults in the USA; while CVD is the leading cause of death and disability in the USA and world accounting for one in three deaths. Zanchetti et al performed a meta-analysis (MA) of randomised controlled trials (RCTs) and found antihypertensive medication use reduced all major types of cardiovascular events and death. Indeed, pharmacological treatment generated reductions in systolic blood pressure (SBP) of 9–10 mm Hg and diastolic BP (DBP) of 4–5 mm Hg decreased the relative risk for all-cause mortality by 11%, cardiovascular morality by 16%, coronary heart disease by 18% and stroke by 36%. Exercise is also recommended as antihypertensive lifestyle therapy because it lowers BP 5–8 mm Hg among adults with hypertension, prevents the development of hypertension and reduces cardiovascular morbidity and mortality. Despite the well-established BP benefits of antihypertensive medications and exercise to prevent, treat and control hypertension, little is known about their

What is already known?

Exercise and medications alone and combined are all effective in reducing blood pressure.

What are the new findings?

The combined blood pressure effects of exercise and medication do not equal the sum of their parts so that they are not additive.

Exercise alone elicits greater blood reductions than medication alone, evidence that is stronger for alternative than traditional forms of exercise.
comparative BP effects alone and combined in the treatment of hypertension.

Two recent network MAs (NMA) addressed this important knowledge gap with slightly different findings. Naci et al were the first to compare the BP lowering effects of exercise vs medications on SBP among healthy adults with normal BP, prehypertension and hypertension.9 They found aerobic and dynamic resistance exercise performed alone or combined reduced SBP by ~9 mm Hg among adults with hypertension, with no detectable difference in the magnitude of the SBP reductions to those resulting from antihypertensive medications.9 Noone et al were the second to compare the BP-lowering effects of exercise and medications among adults with hypertension on BP in RCTs with a sample size of ≥20 participants.10 They concluded there was insufficient evidence to suggest antihypertensive medications were better than exercise in lowering BP. Despite the efforts of these two investigative teams to directly compare the effectiveness of exercise and medication as antihypertensive therapeutic options, the authors acknowledged the exercise arms contained participants treated with medication so that the BP effects reported were not necessarily due to exercise per se, and RCTs that directly compared exercise to medications were not included.

We now perform an NMA of the primary literature and a meta-review of the secondary literature to answer the question: Do the BP effects of exercise and medication combined add up to the BP effects of the sum of their parts among adults with hypertension? The first search involved primary level RCTs that isolated and then directly compared exercise and medication combined (EX+MEDScombined) to exercise (EXalone) and/or medication (MEDSalone) alone among adults with hypertension; and the second involved MAs of RCTs that controlled trials that examined the relationship between exercise and BP among adults with hypertension and reported moderators of the BP response to exercise.

METHODS

This systematic review is consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.11 12

Primary literature search strategy and selection process

After consultation with a medical librarian (JL), we ran comprehensive Boolean searches in PubMed, Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL), SPORTDiscus and the Cochrane Library from 1940 to 21 July 2016 and updated this search in PubMed and Scopus from 21 July 2016 to 26 February 2020. See supplemental digital content 1 (online supplemental SDC 1) for the original and updated search strategy and figure 1 for the selection process. Included studies were RCTs that: (1) involved healthy adults >18 year with hypertension; (2) had an exercise, non-diet group put on antihypertensive medications (EX+MEDScombined) as part of the intervention arm (3) had an exercise, non-diet group not on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or an non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone) and/or a non-exercise, non-diet group put on antihypertensive medications (EXalone).
group put on antihypertensive medications as part of the intervention arm (MEDSalone); (4) reported preintervention and postintervention BP for each treatment arm; (5) reported the intensity, time or type of the acute (i.e., a single session of exercise) or the frequency, intensity, time or type of the chronic (i.e., training) exercise intervention; (6) prior to testing implemented a placebo and medication washout or run-in period and (7) were peer-reviewed articles published in English. Trials involving diet modifications in addition to exercise, or populations with chronic disease(s) (e.g., cancer, coronary artery disease, HIV/AIDS) or animals were excluded.

We also performed and cross referenced the search in online supplemental SDC 2 with an updated search of the 2018 Physical Activity Guidelines Advisory Committee Scientific Report (PAGACSR) that was originally run by BBS from 1 January 2006 the end date of the search that was performed for the 2008 PAGACSR to 17 April 2017. We updated this search from 17 April 2017 to 20 February 2020 in PubMed and the Cochrane Library and from 17 April 2017 to 25 February 2020 in CINAHL (online supplemental SDC 3). We also performed manual searches of reference lists of the qualifying MAs to identify additional studies. See online supplemental SDC 3 for a summary of the PAGACSR secondary literature search strategy and selection process. For the full text review, we included MAs that: (1) contained RCTs and/or controlled trials with a non-exercise, non-diet control group; (2) involved healthy adults >18 year with hypertension; (3) investigated the relationship between exercise and BP; (4) reported preintervention and postintervention BP; (5) performed moderator analyses and (6) were peer-reviewed articles published in English or Chinese. Trials involving diet modifications in addition to exercise, populations with chronic disease(s) (e.g., cancer, coronary artery disease, HIV/AIDS) or animals were excluded.

Secondary literature search strategy and selection process
After consultation with a medical librarian (JL), we ran comprehensive Boolean searches in PubMed from 1940 to 22 October 2016 and updated this search from 22 October 2016 to 18 February 2020 in PubMed and from 22 October 2016 to 6 March 2020 in Scopus. See online supplemental SDC 2 for the original and updated search strategy and figure 2 for the selection process.
original and updated search strategy and figure 3 for the selection process.

Data extraction

The titles, abstracts and full text of the identified articles were independently screened by two reviewers. We used the Joint National Committee Seven BP classification scheme for data extraction purposes because the literature searched was based on this BP classification scheme.14 For the primary level RCTs, in cases when the preintervention and postintervention BP ± SD, SE, or 95% CI were not reported, the authors were contacted to obtain these data. If the author did not respond and the data were available in figure form, Web Plot Digitizer V.4.2 released 7 April 2019 (https://automeris.io/WebPlotDigitizer/) was used to extract these data from the figure. Two abstractors independently extracted data. Disagreements were resolved by discussion.

Risk of bias and methodological study quality assessments

For the primary level literature, we performed a risk of bias (RoB) assessment with the Cochrane RoB Tool V.215 for RCTs that were double-blinded16–22 or blinded23 crossover or double-blinded24 25 or blinded26 27 parallel designs. See online supplemental SDC 4 for a summary of the Cochrane RoB assessment of the RCTs. The RoB V.2 domains assessed were the randomisation process, deviation from intended interventions, missing outcome data, measurement of the outcomes and selection of reported results. For a study to exhibit a low RoB, all domains were judged to be of low RoB; for a study to exhibit some concerns, at least one of the domains was judged to have some concerns; and for a study to exhibit a high RoB at least one domain was judged to have some concerns; and for a study to exhibit a high RoB multiple domains were judged to have some concerns that substantially lowered the confidence in the findings. Heterogeneity between studies was gauged by the Higgins I² statistic with values ranging from 0 (heterogeneity) to 1.00 (greater heterogeneity) and associated p values.28 We also evaluated the potential for publication and other reporting biases for each treatment arm by visually examining the distribution and asymmetry of funnel plots containing the SBP and DBP mean change by the SE of the mean change for EXalone, MEDSalone and EX+MEDScombined.29
For the secondary level literature, we performed a methodological study quality assessment using a modified version of the Assessment of Multiple Systematic Reviews (AMSTAR) containing 18 items that was adapted for exercise related health outcomes such as BP (AMSTAR-ExBP). See online supplemental SDC 5 for a summary of the AMSTAR-ExBP assessment of the study methodological quality of the MAs. Systematic reviews meeting ≤9 (50%) of the items were rated as low, those meeting between 9 and <13 (50%–69%) of the items were rated as moderate, and those meeting ≥13 (≥70%) were rated as high study methodological quality.

**Statistical methods for the primary literature RCTs**

Due to the inherent limitations in the RCTs regarding the sparsity of sample SDs reported and the complexity of the NMA model that was needed, there was no statistical software package available to perform direct treatment arm comparisons of the BP changes from EXalone, MEDSalone, and EX+MEDScombined. Therefore, we developed the statistical model described below to perform an NMA to answer the question: Do the BP effects of exercise and medication combined add up to the BP effects of the sum of their parts among adults with hypertension?

We assumed that there was a total of K RCTs, and within each RCT there were up to three treatment arms j = 1, 2, 3, which denoted EXalone, MEDSalone, and EX+MEDScombined, respectively. For our NMA data, the values of K were: 7 for SBP Acute; 6 for DBP Acute; 5 for both SBP and DBP Chronic; 12 for SBP Total and 11 were: 7 for SBP Acute; 6 for DBP Acute; 5 for DBP Total as reported in table 1. We then let n_{kj}, Y_{kj}, and S_{kj} denote the sample size, SBP and DBP change, and sample SD from each jth treatment arm in the kth RCT for j = 1, 2, 3 and k = 1, 2, …, K. Following Yao et al and Li et al, we assumed the NMA model for Y_{kj} (ie, the SBP or DBP change) as:

\[
\begin{align*}
\mu_{kj} &= \mu_j + \text{ao} \gamma_{kj} + \epsilon_{kj}, \\
\epsilon_{kj} &\sim N(0, \sigma^2_{\epsilon} / n_{kj}),
\end{align*}
\]

where \(\mu_j\) and \(\sigma^2_{\epsilon}\) were the mean and the variance of an individual RCT SBP or DBP change and \(e^{\text{ao}}\) was the SD of the random effect for the jth treatment arm in the kth RCT. Following Li et al, in Equation (1), a 3-dimensional vector of the random effects \(\gamma_{kj} = (\gamma_{k1}, \gamma_{k2}, \gamma_{k3})\) was assumed to follow a 3-dimensional normal distribution with the mean \((0, 0, 0)\) and a 3 x 3 correlation matrix \(p\). Following Lu and Ades, we assumed the correlation matrix \(p\) was specified to reflect small to moderate correlations. As discussed in Gwon et al, the formulation \(e^{\text{ao}}\gamma_{kj}\) in equation (1) greatly improved convergence of the SAS PROC NLMIXED. Within the kth RCT, if \(S_{kj}\) (ie, the sample SD) was available, following Yao et al, we further assumed:

\[
\begin{align*}
\text{Equation (2):} (n_{kj} - 1) S_{kj}^2 &\sim \chi^2_{n_{kj} - 1},
\end{align*}
\]

where \(\chi^2_{n_{kj} - 1}\) denoted the \(\chi^2\) distribution with \((n_{kj} - 1)\) degrees of freedom. For those RCTs in which \(S_{kj}\) was not available, we assumed \(\sigma^2_{\epsilon} = \sigma^2_{\epsilon} K\), where \(K\) is the RCT with the largest sample SD. Under the above NMA model, the mean SBP and DBP changes corresponding to EXalone vs EX+MEDScombined, MEDSalone vs EX+MEDScombined and EXalone vs MEDSalone were denoted as: \(\mu_1 - \mu_3, \mu_2 - \mu_3, \mu_1 + \mu_2 - \mu_3, \) respectively.

We developed SAS Macro BPNA that is available to download from http://merlot.stat.uconn.edu/packages/metapack/resources/sas-macros/ to implement the above NMA model in SAS PROC NLMIXED. Our SAS Macro BPNA automatically calculates the pooled mean SBP or DBP change (Mean), its SE, the df associated with the t-test statistics, and the two-sided p value for each treatment or between treatment arm comparison. For our NMA data, the df ranged from 2 to 9 for each treatment or between treatment arm comparison. Due to the complexity of the NMA model and the sparsity of the NMA RCT data, the pooled SD for each treatment arm was not available or not well defined. For this reason, to account for different df of the t-test statistic, we calculated the effect size (ES) as follows:

\[
\text{Equation (3):} ES = \frac{F_\nu}{\Phi^{-1}(F_\nu (\frac{\mu_1 + \mu_2 - \mu_3}{\text{SE}^{\text{mean}}}))},
\]

where \(F_\nu\) denoted the cumulative distribution function of the t-distribution with \(\nu\) degrees of freedom and \(\Phi^{-1}\) was the inverse of the standard normal distribution function. The ES defined in equation (3) was unified within the same standard normal scale which facilitated the interpretation and comparison between the different treatment arms that were estimated using the NMA data with different sample sizes. The ES in equation (3) also had a one-to-one correspondence with the p value for grading the strength of the BP effect as an ES absolute value of:

- <1.64 insufficient; 1.64–1.96 small; 1.96–2.58 moderate; 2.58–3.29 large; and >3.29 very large, which corresponded to p values of: >0.1; p<0.1–0.05; p<0.05–0.01; p<0.01–0.001 and p<0.001, respectively.

The SBP or DBP change and its corresponding 95% CI from a RCT together with the overall estimated treatment effect and its 95% CI were plotted using R. The funnel plots were produced using R package metafor to visionally inspect the publication bias for EXalone, MEDSalone, and EX+MEDScombined, separately, in the total study sample. Finally, R package emdbook was used to calculate p values of the \(I^2\) statistics.

**Definitions used for the comparison of the treatment arm BP effects**

The primary level RCTs direct comparisons made between EX+MEDScombined and EXalone, and/or MEDSalone, depending on the result, could be assigned the label—synergistic, additive or neutral. To be synergistic, the magnitude of the BP reductions achieved by EX+MEDScombined were greater than EXalone plus MEDSalone or greater than the sum of their parts. To be additive, the magnitude of the BP reductions achieved by EX+MEDScombined were equal to EXalone plus MEDSalone or equal to the sum of their parts. To be neutral, the magnitude of the BP reductions achieved by EX+MEDScombined were equal to EXalone or MEDSalone or no
Table 1  Summary of the BP response to the exercise alone (EXalone), medications alone (MEDSalone), and exercise and medications combined (EX+MEDScombined) treatment arms (mean±SE) compared with control in the acute and chronic RCTs (K=12) and the treatment arm comparisons

<table>
<thead>
<tr>
<th>Trial type (K=# of trials, n=# of subjects)</th>
<th>Treatment arm post-BP vs pre-BP change</th>
<th>Treatment arm comparisons of the BP change between each arm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EXalone</td>
<td>MEDSalone</td>
</tr>
<tr>
<td></td>
<td>SBP</td>
<td></td>
</tr>
<tr>
<td>Acute</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP (K=7, n=88)</td>
<td>-17.76±4.02§</td>
<td>-9.22±1.58‡</td>
</tr>
<tr>
<td>ES=−2.53</td>
<td>ES=−2.85</td>
<td>ES=−2.66</td>
</tr>
<tr>
<td>(I²=0.88)</td>
<td>F=0.42†</td>
<td></td>
</tr>
<tr>
<td>DBP (K=6, n=78)</td>
<td>-5.60±1.65§</td>
<td>-5.48±1.26‡</td>
</tr>
<tr>
<td>ES=−2.03</td>
<td>ES=−2.28</td>
<td>ES=−2.35</td>
</tr>
<tr>
<td>(I²=0.40*)</td>
<td>F=0.53*</td>
<td></td>
</tr>
<tr>
<td>Chronic (K=5, n=254)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>-6.47±1.46§</td>
<td>-12.32±2.18§</td>
</tr>
<tr>
<td>(n=89)</td>
<td>ES=−1.98</td>
<td>ES=−2.17</td>
</tr>
<tr>
<td></td>
<td>(I²=0.07)**</td>
<td>F=0.06§ (f=0.14†</td>
</tr>
<tr>
<td>DBP</td>
<td>-5.08±1.08§</td>
<td>-9.85±0.99‡</td>
</tr>
<tr>
<td>(n=89)</td>
<td>ES=−2.03</td>
<td>ES=−2.58</td>
</tr>
<tr>
<td></td>
<td>(I²=0.00**)</td>
<td>F=0.00* (f=0.08*</td>
</tr>
<tr>
<td>Acute versus chronic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=177)</td>
<td>ES=−2.21</td>
<td>ES=1.08</td>
</tr>
<tr>
<td></td>
<td>(I²=0.25)</td>
<td></td>
</tr>
<tr>
<td>DBP</td>
<td>-0.51±1.97**</td>
<td>3.13±1.50†</td>
</tr>
<tr>
<td>(n=177)</td>
<td>ES=−0.25</td>
<td>ES=1.83</td>
</tr>
<tr>
<td></td>
<td>(I²=0.05)**</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>-14.29±3.14‡</td>
<td>-9.85±1.76†</td>
</tr>
<tr>
<td>(K=12, n=342)</td>
<td>ES=−3.20</td>
<td>ES=−3.59</td>
</tr>
<tr>
<td></td>
<td>(f=0.84*</td>
<td>(n=177)</td>
</tr>
<tr>
<td>DBP</td>
<td>-6.05±1.32‡</td>
<td>-6.24±1.05†</td>
</tr>
<tr>
<td>(K=11, n=332)</td>
<td>ES=−3.12</td>
<td>ES=−3.58</td>
</tr>
<tr>
<td></td>
<td>(f=0.38*</td>
<td>(n=167)</td>
</tr>
</tbody>
</table>

P values are calculated based on a t distribution with df ranging from 2 to 9. Effect sizes are converted to the standard normal scale. The strength of an effect size is in the absolute value: <1.64 insufficient**, 1.64–1.96 small§, 1.96–2.58 moderate‡, 2.58–3.29 large and >3.29 very large†, which correspond to P values: >0.1, P<0.1–0.05, P<0.05–0.01, P<0.01–0.001, P<0.001, respectively.

*P<0.001; **P<0.0001. BP differences posttreatment versus pretreatment arm, acute versus chronic RCTs, and between treatment arm comparisons.

BP, blood pressure; DBP, diastolic blood pressure; ES, effect size; RCT, randomised controlled trials; SBP, systolic blood pressure;
added benefit (or harm). In addition, if the BP effects between EX+MEDScombined were greater than EXalone or MEDSalone, the BP effects of EX+MEDScombined were considered to potentiate the antihypertensive effects of either alone. For the MA moderator analyses, if the authors did not disclose whether medication was a significant moderator or not, we considered the BP effects of EX+MEDScombined compared with EXalone and/or MEDSalone to be neutral or no added benefit (or harm).

The grading of the evidence
For both literatures, we used the grading system of the 2018 PAGACSR and graded the evidence as strong, moderate, limited or ‘not assignable’ based on grading criteria that included applicability, generalisability, RoB/study limitations, quantity and consistency of results across studies, and magnitude and precision of the BP effect. More detailed information about the grading of evidence rubric we used can be found in the 2018 PAGAC scientific report13 45 46

RESULTS
The primary literature
To maximise coverage of the literature we conducted two searches. The first was run in PubMed, Scopus, CINAHL, SPORTDiscus and the Cochrane Library to 21 July 2016 and updated in PubMed and Scopus on 26 February 2020 yielding 33,039 potentially qualifying trials (online supplemental SDC 1, figure 1). Of these, 12 RCTs qualified.16–27

Study and sample characteristics
Online supplemental SDC 6 contains the descriptions of the sample, study and intervention characteristics of the seven qualifying acute and online supplemental SDC 7 the five chronic RCTs. There was a total of 342 subjects (n=88 in the acute RCTs; n=254 in the chronic RCTs) with a mean of 28.5±32.2 subjects per RCT ranging from 8 to 120 subjects. Participants were mostly physically inactive, middle-aged to older adults with an untreated resting SBP/DBP of 149.3±11.6/93.4±7.7 mm Hg. A history of antihypertensive treatment was disclosed in seven RCTs (n=5 acute; n=2 chronic). Of these, two contained a mix of treated and untreated subjects,16 24 two untreated subjects17 26 and three treated subjects.20–22 Prior to testing, all investigators implemented a placebo and medication washout or run-in period that averaged 3.4±2.0 week. When reported, 94% of the subjects in the acute RCTs were men, 74% of the subjects in the chronic RCTs were women and 60% of the subjects in the total sample were women.

Of the 12 qualifying RCTs, seven were acute double-blinded cross-over designs,16–22 one was a chronic blinded cross-over design,23 two were chronic double-blinded parallel designs,24 25 and two were blinded parallel designs.26 27 Five of the acute RCTs had three treatments—EXalone, MEDSalone, and EX+MEDScombined,17 19–22 while Wilcox et al16 and Cléroux et al28 had two treatments—EXalone and EX+MEDScombined. Only one of the chronic interventions had three treatments,23 while Kelenen et al28 and Ohta et al29 had EXalone and EX+MEDScombined, and Maruf et al30 had MEDSalone and EX+MEDScombined. The antihypertensive medications examined included beta-blockers (K=3, two acute and two chronic RCTs), calcium channel blockers (K=3, one acute and two chronic RCTs), angiotensin converting enzyme inhibitors (K=3, two acute and one chronic RCTs), angiotensin I or II receptor blockers (K=3, two acute and one chronic RCTs) and diuretics (K=1, chronic RCT).

The acute exercise interventions were primarily aerobic16–19 21–22 except Queiroz et al20 which involved dynamic resistance exercise and were of moderate to vigorous intensity for 38.8±7.6 min per session. The chronic exercise interventions were also mostly aerobic23 25–27 except for Kelenen et al28 which involved concurrent exercise training and were of moderate to vigorous intensity performed 3 day/week for 37.0±15.7 min per day for 9.8±3.5 week. All investigators measured BP preintervention and postintervention by auscultation in the laboratory.16–22 24–27 except Radaelli et al25 who reported ambulatory BP only.

The BP response to exercise alone (EXalone), medications alone (MEDSalone), and exercise and medications combined (EX+MEDScombined)
A summary of the BP response (mean±SE) to the three treatments compared with control is displayed in the left side of table 1. Furthermore, forest plots of the BP response to the three treatments compared with control are in online supplemental SDC 8 for EXalone, online supplemental SDC 9 for MEDSalone and online supplemental SDC 10 for EX+MEDScombined. Among the total sample, SBP and DBP were significantly reduced postintervention vs preintervention in each treatment arm by 10–16 mm Hg for SBP and 6–8 mm Hg for DBP (Ps<0.01, Ps<0.001), with a large strength of SBP and DBP effect for EXalone and very large strength of SBP and DBP effect for MEDSalone and EX+MEDScombined. In the acute RCTs, the BP reductions postintervention versus preintervention in the three treatments compared with control were 9–18 mm Hg for SBP and 6–7 mm Hg for DBP (0.05≤Ps<0.10), with a moderate strength of SBP and DBP effect for EXalone and a moderate strength of DBP effect and large strength of SBP effect for MEDSalone and EX+MEDScombined. In the chronic RCTs the BP reductions were 7–15 mm Hg for SBP and 5–10 mm Hg for DBP (0.05≤Ps<0.10), with a moderate strength of SBP and DBP effect for EXalone and a moderate strength of DBP effect and large strength of SBP effect for MEDSalone and EX+MEDScombined. The BP reductions for EXalone were greater in the acute than chronic RCTs by 11 mm Hg (Ps<0.05) with a moderate strength of SBP effect; whereas the DBP reductions for MEDSalone were greater in the chronic than the acute RCTs by 3 mm Hg.
(0.05 ≤ P < 0.10), with a small strength of DBP effect. There were no differences in the DBP reductions for EXalone, SBP reductions for MEDSalone, and the SBP and DBP reductions for EX+MEDScombined between the acute and chronic RCTs (P > 0.05).

**Risk of bias**

Using the Cochrane RoB tool V.2,15 we found most of the RCTs exhibited high levels of RoB (k=10, 83.3%), with 83.3% exhibiting some concerns primarily for missing measurement outcomes and selection of reported results, and 70% exhibiting some concerns with the randomisation process (online supplemental SDC 4). The I² statistic in table 1 averaged 0.29 and ranged from 0.00 (homogeneity) to 0.88 (greater heterogeneity) with greater heterogeneity among the acute RCTs (0.53) than chronic RCTs (0.06). Visual inspection of the distribution and asymmetry of the funnel plots of the SBP and DBP mean change versus SE are in online supplemental SDC 11 for EXalone, online supplemental SDC 12 for MEDSalone, and online supplemental SDC 13 for EX+MEDScombined. The funnel plots revealed 28%–60% of the studies fell outside of the inverted triangle indicating there was publication bias or other reporting bias and between study heterogeneity for the SBP and DBP responses to EXalone, MEDSalone and EX+MEDScombined.

The treatment arm comparisons of the BP response to exercise alone (EXalone), medications alone (MEDSalone), and exercise and medications combined (EX+MEDScombined)

A summary of the BP response (mean±SE) between the treatment arm comparisons is displayed in the right side of table 1. When comparing EXalone to EX+MEDScombined, the SBP and DBP reductions were not different in the total sample and acute RCTs (P ≥ 0.10). However, in the chronic RCTs, the SBP reductions were greater by 8 mm Hg for EX+MEDScombined than EXalone (P < 0.05, P < 0.10), with a small strength of SBP effect; while the DBP reductions were not different for EXalone vs EX+MEDScombined (P ≥ 0.10). The SBP reductions were 10 mm Hg greater for EXalone vs EX+MEDScombined in the acute than the chronic RCTs (P < 0.05), with a moderate strength of SBP effect; whereas the DBP reductions for EXalone vs EX+MEDScombined were not different between the acute and chronic RCTs (P ≥ 0.10). These findings reveal no BP benefit of EX+MEDScombined over EXalone except for perhaps a small advantage of EX+MEDScombined over EXalone for SBP in the chronic RCTs.

When comparing MEDSalone to EX+MEDScombined, the SBP reductions in the total sample were greater by 6 mm Hg (P < 0.01) and acute RCTs by 7 mm Hg (P < 0.05) for EX+MEDScombined than MEDSalone with a large and moderate strength of SBP effect, respectively; whereas the DBP reductions were not different in the total sample and acute and chronic RCTs for MEDSalone vs EX+MEDScombined (P ≥ 0.10). Furthermore, the SBP and DBP reductions for MEDSalone vs EX+MEDScombined were not different between the acute and chronic RCTs (P > 0.05). These findings reveal an advantage of EX+MEDScombined over MEDSalone for SBP but not DBP.

When comparing EXalone plus MEDSalone to EX+MEDScombined in the total sample and acute RCTs, the SBP (P ≤ 0.05) and DBP (0.05 ≤ P ≤ 0.10) reductions were greater for EXalone plus MEDSalone vs EX+MEDScombined by 8–10 mm Hg for SBP and 5 mm Hg for DBP, with a moderate to large strength of SBP effect and a small to moderate strength of DBP effect. In contrast, the SBP and DBP reductions were not different for EXalone plus MEDSalone vs EX+MEDScombined in the chronic RCTs or between the acute and chronic RCTs (P ≥ 0.10). Therefore, in the total sample the SBP and DBP effects of EX+MEDScombined were not additive nor synergistic, a result largely driven by the acute RCTs.

When comparing the EXalone to MEDSalone in the total sample, the SBP and DBP reductions were not different for EXalone than MEDSalone (P > 0.10). However, in the acute RCTs, the SBP reductions were greater by 8 mm Hg for EXalone than MEDSalone (P < 0.05), with a moderate strength of SBP effect, but the DBP reductions were not different for EXalone than MEDSalone (P > 0.10); while in the chronic RCTs the DBP reductions were greater for MEDSalone vs EXalone by 5 mm Hg (0.05 ≤ P ≤ 0.10), with a small strength of DBP effect, but the SBP reductions were not different for EXalone than MEDSalone (P > 0.10). Furthermore, the SBP reductions were greater by 14 mm Hg (P ≤ 0.01) and DBP by 4 mm Hg (0.05 ≤ P ≤ 0.10) for EXalone vs MEDSalone between the acute than chronic RCTs, with a large strength of SBP effect and small strength of DBP effect, respectively. In the total sample, EXalone is equally effective as MEDSalone in lowering BP; however, EXalone is moderately more effective than MEDSalone in lowering SBP in the acute RCTs and MEDSalone elicits a small advantage in lowering DBP in the chronic RCTs.

In summary, in the total sample, there is a large to very large strength of BP effect for EXalone, MEDSalone, and EX+MEDScombined eliciting SBP reductions ranging from 10 to 16 mm Hg and DBP ranging from 6 to 8 mm Hg. When directly comparing the BP reductions from EXalone and/or MEDSalone to EX+MEDScombined for the total sample: (1) EXalone and EX+MEDScombined appear equally effective in lowering SBP and DBP, noting the exception of SBP in the acute RCTs in which EX+MEDScombined conferred a small advantage over EXalone; (2) EX+MEDScombined is more effective than MEDSalone in lowering SBP, largely driven by the acute RCTs, but appears equally as effective as MEDSalone in lowering DBP; (3) EXalone plus MEDSalone elicits greater SBP and DBP reductions than EX+MEDScombined, largely driven by the acute RCTs; and (4) EXalone and MEDSalone appear equally effective in lowering SBP and DBP, noting the exception of DBP in the chronic RCTs in which MEDSalone conferred a small advantage over EXalone. Now to answer the question—the BP reductions of EX+MEDScombined do not add up to the sum of the BP reductions of each treatment alone indicating they are not additive nor synergistic. Yet, when directly comparing the three treatment arms, EXalone appears equally as effective as
MEDSalone and EX+MEDScombined in lowering SBP and DBP. Furthermore, EX+MEDScombined is more effective than MEDSalone in lowering SBP, while both appear equally effective in lowering DBP.

Grading of the evidence in the primary literature

Strong evidence demonstrates EXalone, MEDSalone, and exercise and medication combined reduce BP among adults with hypertension. Grade: Strong.

Strong evidence demonstrates exercise and medication combined elicit BP reductions of less magnitude than the sum of EXalone plus MEDSalone among adults with hypertension. Grade: Strong.

Strong evidence demonstrates exercise and medication combined potentiate the magnitude of the SBP reductions from medications alone among adults with hypertension. Grade: Strong.

Insufficient evidence is available to determine whether exercise and medication combined potentiate the DBP reductions from medicine alone among adults with hypertension. Grade: not assignable.

Insufficient evidence is available to determine whether exercise and medication combined potentiate the SBP reductions from EXalone among adults with hypertension. Grade: limited.

Insufficient evidence is available to determine whether exercise and medication combined potentiate the DBP reductions from EXalone among adults with hypertension. Grade: limited.

Insufficient evidence is available to determine whether exercise and medication combined potentiate the magnitude of the SBP reductions from medications alone among adults with hypertension. Grade: limited.

Evidence on the influence of antihypertensive medication on the BP response to exercise

Of the 13 qualifying MAs, six did not report if medication was a significant moderator or not, and six reported medication was not a significant moderator and six found medication was a significant moderator of the BP response to exercise.

MacDonald et al. reported moderate intensity, dynamic resistance training performed on average 3 day/week for 14 week lowered SBP 5.7 mm Hg (−9.0 to −2.7) and DBP 5.2 mm Hg (−8.4 to −1.9) among 667 adults with hypertension (−28% of the total sample). In addition, 15% of the total sample was on medication, but 92% of the trails did not disclose information on medication use. Greater SBP/DBP reductions occurred among samples exercising and not taking medication (−4.3 mm Hg (−6.2 to −2.2)/−3.5 mm Hg (−5.0 to −2.1)) than those exercising and taking medication (−0.4 mm Hg (−3.8, 3.0)/−1.2 mm Hg (−3.4, 1.0)) suggesting the BP benefits of EXalone were greater than those of EX+MEDS combined. However, the authors urged caution in interpreting these findings because they pertained to the total sample and not to adults with hypertension per se, there was a small percentage of the sample taking medications, and a general lack of disclosure of this information.

The secondary literature

To maximise coverage of the secondary literature we conducted two searches. The first was run in PubMed to 22 October 2016 and updated in PubMed on 18 February 2020 and Scopus from 22 October 2016 to 6 March 2020 and yielded 182 potentially qualifying trials (online supplemental SDC 2, figure 2). Of these, a total of six MAs of which four involved RCTs and two controlled trials qualified. This search was cross referenced with the PAGACSR original search that was run from 1 January 2006 to 7 April 2017 and updated on 20 February 2020 in PubMed and the Cochrane Library, and updated on 25 February 2020 in the CINAHL databases. The PAGACSR original and updated searches yielded 1210 potentially qualifying trials (online supplemental SDC 3, figure 2). Of these, eight MAs of RCTs and three of controlled trials qualified, and they included the six qualifying MAs from the online supplemental SDC 2 search. In addition, we performed manual searches of the references lists within the MAs and examined electronic journal table of contents and medical search engines routinely sent to the investigators related to exercise and hypertension from which two additional MAs were identified, one of which included RCTs and one RCTs and controlled trial.

Study and sample characteristics

See online supplemental SDC 14 for the description of the sample, study and intervention characteristics categorised by exercise modality of the 13 qualifying MAs of which nine were MAs of RCTs and 4 MAs of RCTs and controlled trials with a range of 8–93 trials per MA. Two MAs involved aerobic exercise training, one acute and two chronic (ie, training) dynamic resistance exercise, one chronic aerobic and resistance combined (ie, concurrent), and seven chronic complementary and alternative types of exercise that included Daduanjin, Qigong, Tai Chi, Wuqinxi, Yijinjing and Yoga. The sample size was 28 468 adults >18 years, ranging from 572 to 5223 participants. When the data were provided, the samples were generally an equal mix of men and women, and mostly Caucasian or Asian. The overall study methodological study quality of the literature was high, with 54% scoring moderate and 46% high on the AMSTARExBP (online supplemental SDC 5).
Medsalone (−7.5 mm Hg (−11.4−3.6)/−3.6 mm Hg (−5.2 to
−1.8)) and qigong combined with medication than
Qigong EXalone (−12.0 mm Hg (−15.6, −8.5)/−5.3 mm
Hg (−8.1 to −2.4))48 56; while Wang et al found greater
SBP/DBP reductions with Tai Chi combined with
medication than Tai Chi EXalone (−9.3 mm Hg (−10.9
to −7.8)/−7.2 mm Hg (−7.7 to −6.6))50. Furthermore,
xiong et al found qigong EXalone (−7.9 mm Hg (−16.8,
1.0)/−6.1 mm Hg (−9.6−2.6))50 Zhong et al found Tai
Chi EXalone (−9.0 mm Hg (−14.0, −4.1)/−5.6 mm Hg
(−8.8 to −2.4)),38 and wang et al55 found Tai Chi EXalone
(−14.3 mm Hg (−14.31, −14.29)/−6.0 mm Hg (−6.01
to −5.99)) elicited greater SBP/DBP reductions than
Medsalone. Collectively, the findings of jin et al,48 xiong
et al48 56 and wang et al55 indicated that complementary
and alternative forms of EX+Medscombined elicited
greater BP reductions than Medsalone. In addition,
the findings of xiong et al,56 Zhong et al,58 and wang et
al55 demonstrated that complementary and alternative
forms of EXalone resulted in greater BP reductions than
Medsalone.

In summary, six MAs did not report the results of their
moderator analyses involving medication17 49 52 53 57 59 and
one54 found medication was not a significant moderator
of the BP response to exercise suggesting EX+Medscom-
bined added no BP benefit to EXalone, findings that are
consistent with those of naci et al8 and noone et al.10 One
MA found EX+Medscombined attenuated the BP bene-
fits of EXalone51. Four MAs found greater BP reductions
with EX+Medscombined than Medsalone48 50 55 56 and
three MAs found EXalone elicited greater BP reductions
than Medsalone.55 56 58

The grading of the evidence of the secondary literature
Strong evidence demonstrates EXalone, Medsalone,
and exercise and medication combined reduce BP
among adults with hypertension. Grade: strong.

Strong evidence demonstrates exercise and medication
combined potentiate the magnitude of the BP reduc-
tions from Medsalone among adults with hypertension.
Grade: strong.

Moderate evidence indicates EXalone elicits greater BP
reductions than Medsalone among adults with hyper-
tension. Grade: moderate.

Insufficient evidence is available to determine whether
the exercise and medication combined potentiate the BP
reductions from EXalone among adults with hyper-
tension. Grade: not assignable.

DISCUSSION
The answer to the question: do the combined BP effects
of exercise and antihypertensive medications add up to
the sum of their parts?

We have conducted the first evidence-based, compre-
prehensive systematic NMA and meta-review on two literature
levels to compare the effectiveness of EX+Medscom-
bined to EXalone and/or Medsalone, on BP among
adults with hypertension. The first search involved
primary level RCTs that isolated and directly compared
EX+Medscombined to EXalone and/or Medsalone,
and the second involved MAs of RCTs and controlled
trials on exercise and BP that performed moderator
analyses. A summary of the grading of the evidence-
based conclusion statements on the BP response to
EXalone, Medsalone, and EX+Medscombined is shown in
table 2.

In total, there were eight conclusion statements made
from the primary literature of which three were strong,
three limited, and two not assignable; and from four
of the secondary literature of which three were strong,
one moderate and one not assignable. Strong evidence
from the RCTs (online supplemental SDC 6 and 7
and table 2) and MAs (online supplemental SDC 14
and table 2) demonstrates EXalone, Medsalone, and
EX+Medscombined reduce BP by 2–18 mm Hg among
adults with hypertension. Strong evidence from the
RCTs demonstrates the combined BP effects of exercise
and medications are less than the sum of either alone
by 5–8 mm Hg. Despite finding the combined BP effects
of exercise and medication are not additive or syner-
gistic, strong evidence from the RCTs indicates that when
combined, they potentiate the SBP effect of Medsalone
by 6 mm Hg with traditional types of exercise (ie, aerobic
and resistance); whereas there was insufficient evidence
to make any conclusions about DBP. In addition, there
was strong evidence from the MAs that EX+Medscom-
bined potentiate the SBP and DBP effects of Medsalone
up to 14 mm Hg with alternative types of exercise (ie,
daduanjin, Qigong, Tai Chi, Wuqinxi, Yijinjing and
Yoga). The evidence from the RCTs and MAs was limited
to not assignable, and thus, only suggestive that EX+Meds-
combined may potentiate the BP reductions from
EXalone among adults with hypertension. The evidence
of the comparative effects of EXalone and Medsalone
was mixed with limited evidence from the acute RCTs
indicating EXalone elicits greater SBP reductions than
Medsalone by 9 mm Hg; whereas in the chronic RCTs
Medsalone elicits greater DBP reductions than EXalone
by 5 mm Hg; whereas for the MAs moderate evidence
indicated that alternative forms of EXalone elicits greater
BP reductions than Medsalone by 6–9 mm Hg.

The benefits of lowering BP among those with hyper-
tension are undisputable, however, the methods by which
the BP reductions are achieved are a topic of debate
regarding their comparative effectiveness.9 10 60–65 We
found EXalone, Medsalone and EX+Medscombined all
reduce BP by 2–17 mm Hg. BP reductions of 5–10 mm
Hg decrease the relative risk for all-cause mortality 11%,
cardiovascular morality 16%, coronary heart disease 18%,
and stroke 36% substantiating the importance of each
of these approaches to treat hypertension.3 For the first
time, we have conducted an NMA of RCTs that isolated
the BP effects of EX+Medscombined to EXalone and/or
Medsalone (online supplemental SDC 6 and 7). In
this way, we were able to deliver strong evidence that the
BP effects of exercise and medication combined are not

additive to the BP effects of either alone. However, when combined, they potentiate the BP effects of MEDSalone, BP benefits that appear twice as large for alternative than traditional types of exercise. Furthermore, limited to moderate evidence in the RCTs and MAs, respectively, suggests that EXalone may elicit greater SBP reductions than MEDSalone. 

Collectively, our novel findings should temper the widely held belief that antihypertensive medications reduce BP more than exercise because: alone or combined, they lower BP; when combined they potentiate the BP effects of MEDSalone; and EXalone elicits greater BP reductions than medications alone, although the evidence is stronger for alternative than traditional types of exercise. An important take home message is that when combined, exercise and medication strengthen the BP effects of MEDSalone and should be recommended and implemented as indicated according to existing professional treatment algorithms.1 63–66

**Comparison to the literature**

Our findings are in accord with the recent NMA of Naci et al9 and Noone et al.10 Despite the efforts of these two investigative teams to compare the effectiveness of EXalone to MEDSalone as antihypertensive therapeutic options, the exercise arms in these NMA contained participants treated with medication so that the BP effects reported for exercise were not necessarily due to exercise per se, and the medication comparator may have included placebo, usual care, and other medications in addition antihypertensive medications. Naci et al9 and Noone et al10 found traditional types of exercise (that were often combined with medications) reduced BP to similar levels as the medication comparator. However, due to the admixture of the treatment comparisons in these NMA, it was not possible to truly isolate the BP effects of EXalone, MEDSalone, and EX+MEDScombined from one another as we have done in this NMA and meta-review.

Reasons why alternative types of exercise when combined with medications potentiate the BP benefits of MEDSalone to levels twice as large as those that result for traditional types of exercise are not clear. A possible explanation is provided by Wu et al in their MA involving Yoga training among 3517 participants in which they found the greatest BP reductions occurred

---

**Table 2** Summary of the grading of the evidence for the conclusion statements on the blood pressure (BP) response to the exercise alone, medications alone, and exercise and medications combined and their comparisons among adults with hypertension

<table>
<thead>
<tr>
<th>Conclusion statement</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong evidence demonstrates exercise alone, medication alone and exercise and medication combined reduce BP among adults with hypertension.</td>
<td>Strong16–27</td>
</tr>
<tr>
<td>Strong evidence demonstrates exercise and medication combined elicit BP reductions of less magnitude than the sum of exercise alone plus medication alone among adults with hypertension.</td>
<td>Strong16–23</td>
</tr>
<tr>
<td>Strong evidence demonstrates exercise and medication combined potentiate the magnitude of the SBP reductions from medication alone among adults with hypertension.</td>
<td>Strong16–27</td>
</tr>
<tr>
<td>Insufficient evidence is available to determine whether exercise and medication combined potentiate the DBP reductions from medicine alone among adults with hypertension.</td>
<td>Not assignable16–27</td>
</tr>
<tr>
<td>Limited evidence suggests exercise and medication combined potentiate the SBP reductions from exercise alone among adults with hypertension.</td>
<td>Limited16–24 26</td>
</tr>
<tr>
<td>Insufficient evidence is available to determine whether exercise and medication combined potentiate the DBP reductions from exercise alone among adults with hypertension.</td>
<td>Not assignable16–24 26</td>
</tr>
<tr>
<td>Limited evidence suggests exercise alone elicits greater SBP reductions than medication alone among adults with hypertension.</td>
<td>Limited16–23</td>
</tr>
<tr>
<td>Limited evidence suggests medication alone elicits greater DBP reductions than exercise alone among adults with hypertension.</td>
<td>Limited16–23</td>
</tr>
<tr>
<td>Strong evidence demonstrates exercise alone, medication alone, and exercise and medication combined reduce BP among adults with hypertension.</td>
<td>Strong47–59</td>
</tr>
<tr>
<td>Strong evidence demonstrates exercise and medication combined potentiate the magnitude of the BP reductions from medication alone among adults with hypertension.</td>
<td>Strong48 50 55 56</td>
</tr>
<tr>
<td>Moderate evidence indicates exercise alone elicits greater BP reductions than medication alone among adults with hypertension.</td>
<td>Moderate55 56 58</td>
</tr>
<tr>
<td>Insufficient evidence is available to determine whether the exercise and medication combined potentiate the BP reductions from exercise alone among adults with hypertension.</td>
<td>Not assignable.47 49 52 53 57 59</td>
</tr>
</tbody>
</table>

*The conclusions in the primary literature are largely based on evidence from the randomised controlled trials involving acute and chronic aerobic and resistance exercise.
†The conclusions in the secondary literature are largely based on evidence from the meta-analyses involving chronic complementary and alternative types of exercise.

DBP, diastolic BP; SBP, systolic BP.
among Yoga interventions that included breathing techniques and meditation and mental relaxation. Of note, the new International Society of Hypertension Guidelines have added stress reducing measures such as transcendental meditation and Yoga to their recommended lifestyle modifications and the American College of Sports Medicine has expanded their exercise recommendations to include alternative forms of exercise. In a more recent MA involving Tai Chi training among 3223 participants, Wu et al found the greatest BP reductions occurred among trials published in Chinese than English partially attributed to the lower methodological study quality of the Chinese than English literature. Nonetheless, the MAs from which the treatment comparisons were made in our meta-review were of moderate to high quality. Further research is also warranted to gain insight into why mind body types of exercise appear to confer greater BP benefit than MEDSalone.

Limitations

Several limitations of this systematic NMA and meta-review should be noted. The RCTs (online supplemental SDC 6 and 7) tended to be older, some involved medications that have become outdated in clinical practice, assumptions were made in our NMA statistical model due to missing data, and they exhibited a high RoB largely due to concerns about the randomisation process and the inability to hide the BP effects of medication from the investigators taking measurements during testing. In addition, the RCTs involved aerobic and resistance exercise and did not disclose ethnicity, while the MAs involved mostly Caucasians and Asians and had a nearly an equal mix of aerobic and resistance exercise and alternative types of exercise. Nearly half of the MAs did not report whether medication was a significant moderator or not. Nonetheless, the strengths are this is a large, evidenced-based comprehensive systematic NMA and meta-review on two literature levels that included RCTs that for the first time isolated the BP effects of each treatment arm being compared in our NMA; and high methodological quality MAs with moderator analyses that compared the treatments arms among adults with hypertension.

CONCLUSIONS

We have conducted the first large, comprehensive evidenced-based systematic NMA and meta-review adhering to high contemporary standards on two literature levels that compared the effectiveness of EX+MEDScombined to EXalone and/or MEDSalone on BP among adults with hypertension. We found the BP effects of EX+MEDScombined were not additive or synergistic. Yet, the combined effects of exercise and medication bolstered the BP effects of MEDSalone to treat hypertension, and although the evidence was not as robust, EXalone elicited greater BP reductions than medications alone. Another novel finding that merits further investigation is alternative types of exercise appear to exert superior BP benefits than traditional types of exercise. Thus, EXalone, MEDSalone and EX+MEDScombined are all effective antihypertensive therapeutic approaches. However, their combined BP effects are stronger than MEDSalone in the treatment of hypertension.

Acknowledgements

The authors gratefully acknowledge the contributions of The 2018 Physical Activity Guidelines Advisory Committee who were involved in the initial search of the secondary literature that included David M. Buchner, Wayne Campbell, Loretta DiPietro, Kirk I. Erickson, Charles H. Hillman, John M. Jakicic, Kathleen F. Janz, Peter T. Katzmarzyk, Abby C. King, William E. Kraus, Richard F. Macko, David X. Marquez, Anne McTiernan, Russell R. Pate, Linda S. Pescatello, Kenneth E. Powell and Melicia C. Whitt-Glover; Anne Brown Rodgers, U.S. Department of Health and Human Services (HHS) consultant for technical writing support; and ICF librarians, abstractors, and HHS support staff. ICF staff collaborated with the Committee in the design and conduct of the searches by assisting with the development of the analytical frameworks, inclusion/exclusion criteria, and search terms for each primary question; using those parameters, ICF performed the literature searches. The authors also acknowledge Lynette L. Craft, Ph.D., FACSIM, Chief Science Officer for the American College of Sports Medicine for her review of the manuscript, and Christina Day, University of Connecticut Department of Kinesiology graduate research assistant for her assistance with data extraction from the figures.

Contributors

(1) Concept, design, and data interpretation; (2) drafting of the manuscript and (3) final approval.

Funding

The University of Connecticut Centre for Excellence in Teaching and Learning funded YW.

Competing interests

None declared.

Patient consent for publication

Not required.

Ethics approval

Institutional board approval was not required as this NMA and meta-review did not involve data collection with human subjects but involved systematic review of data that had been previously collected.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ids

Linda S Pescatello http://orcid.org/0000-0002-5841-798X
Yin Wu http://orcid.org/0000-0001-8647-4706
Ming-Hui Chen http://orcid.org/0000-0003-1935-2447

REFERENCES

Ammar T
and in combination with a calcium channel blocker or an angiotensin
hypertension on two antihypertensive drugs: a randomized clinical
activity, atenolol and the combination on ambulatory blood pressure
in individuals with metabolic syndrome. Int J Sports Med
chronic ingestion of propranolol or metoprolol on the physiological
risk of bias in randomized trials. A language and environment for statistical computing.
Viethscherbauer W, Combining meta-analyses in R with the metafor


